| Authors: |
Masri A; Oregon Health and Science University, Portland, Oregon, USA. Electronic address: masria@ohsu.edu., Judge DP; Medical University of South Carolina, Charleston, South Carolina, USA., Ruberg FL; Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts, USA., Gillmore JD; National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom., Grodin JL; Parkland Health and Hospital System, Dallas, Texas, USA; University of Texas Southwestern Medical Center, Dallas, Texas, USA., Obici L; Amyloidosis Research and Treatment Center, Pavia, Italy., Maurer MS; Columbia University Irving Medical Center, New York, New York, USA., Fontana M; National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom., Poulsen SH; Aarhus University Hospital, Aarhus, Denmark., van der Meer P; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Cheng RK; University of Washington, Seattle, Washington, USA., Cuddy SAM; Brigham and Women's Hospital, Boston, Massachusetts, USA., Ambardekar AV; University of Colorado, Aurora, Colorado, USA., Xiong K; BridgeBio Pharma, Inc, San Francisco, California, USA., Cao X; BridgeBio Pharma, Inc, San Francisco, California, USA., Murtagh G; BridgeBio Pharma, Inc, San Francisco, California, USA., Siddhanti S; BridgeBio Pharma, Inc, San Francisco, California, USA., Castaño A; BridgeBio Pharma, Inc, San Francisco, California, USA., Tamby JF; BridgeBio Pharma, Inc, San Francisco, California, USA., Fox JC; BridgeBio Pharma, Inc, San Francisco, California, USA., Alexander KM; Stanford University School of Medicine, Stanford, California, USA., Witteles R; Stanford University School of Medicine, Stanford, California, USA; Stanford Amyloid Center, Stanford, California, USA. |
